S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2014 and Provides Financial Expectations for 2015 (2015/2/24)|
|Alkermes Announces Positive Topline Results From Phase 1 Study of ALKS 8700 for Treatment of Multiple Sclerosis (2015/2/9)|
|Alkermes Announces Positive Results of Phase 2 Clinical Trial of ALKS 3831 in Schizophrenia (2015/1/7)|
|Alkermes Announces Positive Results From Study of ALKS 5461 for Treatment of Major Depressive Disorder (2015/1/6)|
|Alkermes Announces Results From Phase 1 Study of ALKS 7106 (2015/2/24)|
|Alkermes shares up 5% on news of positive trial for schizophrenia drug (2015/1/7)|
|Alkermes Appoints Mark Namchuk, Ph.D., As Senior Vice President of Research, Pharmaceutical and Nonclinical Development (2015/2/23)|
|Alkermes Announces Initiation of Clinical Study of Extended Durations of Aripiprazole Lauroxil for Treatment of Schizophrenia (2014/12/15)|
|Alkermes Announces Webcast of Analyst and Investor Event on March 2, 2015 (2015/2/23)|
|Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2014 Financial Results (2015/2/17)|
Click above to view more mutual fund data and stats for alks - Alkermes PLC.